SCHEMBL2693682

SCHEMBL2693682

O=C(c1ccc(CN2CCC3(CC2)CCN(Cc2cccs2)CC3)cc1)N(Cc1ncc[nH]1)Cc1ncc[nH]1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.67
CYP2D6 P10635 7/20 0.40
CYP3A4 P08684 7/20 0.40
TSHR P16473 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2C9 P11712 4/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HIF1A Q16665 1/20 0.40
OPRD1 P41143 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CHRM2 P08172 3/20 0.38
USP2 O75604 2/20 0.38
CYP1A2 P05177 2/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CHRM4 P08173 1/20 0.37
CTSD P07339 1/20 0.37
CHRM3 P20309 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1795986 0.96 CXCR4 (0.74) CXCR4CYP2D6CYP3A4TSHRCYP2C19
SCHEMBL1793933 0.96 CXCR4 (0.74) CXCR4CYP2D6CYP3A4TSHRCYP2C19
SCHEMBL2693827 0.96 CXCR4 (0.69) CXCR4CYP2D6CYP3A4TSHRCYP2C19
SCHEMBL2692809 0.96 CXCR4 (0.69) CXCR4CYP2D6CYP3A4TSHRCYP2C19
SCHEMBL2694761 0.95 CXCR4 (0.70) CXCR4CYP2D6CYP3A4TSHRCYP2C19
SCHEMBL2693103 0.93 CXCR4 (0.70) CXCR4CYP2D6CYP3A4TSHRCYP2C19
SCHEMBL2695337 0.93 CXCR4 (0.70) CXCR4CYP2D6CYP3A4TSHRCYP2C19
SCHEMBL2696530 0.89 CXCR4 (0.60) CXCR4OPRD1CHRM2CHRM3
SCHEMBL1797551 0.89 CXCR4 (0.60) CXCR4OPRD1CHRM2CHRM3
SCHEMBL2697466 0.87 CXCR4 (0.60) CXCR4CYP2D6CYP3A4TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US claimed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885CYP2D6 2687/4885CYP3A4 3747/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885CYP2D6 2851/4885CYP3A4 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.